Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retaspimycin + Everolimus in KRAS Mutant NSCLC
NCT01427946Phase 2Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Jul 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of retaspimycin in non-small cell lung cancer (NSCLC), sponsored by Infinity Pharmaceuticals, Inc.. Started Jul 2011; status: completed.
02
Drugs
retaspimycin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01427946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01427946.